LAG3 and neoplasm: Tobemstomig is designed with 20-fold higher binding affinity to PD-1 over LAG-3, resulting in an avidity-driven selectivity gain to PD-1 and LAG-3 co-expressing activated effector T (Teff) cells in the tumor over regulatory T (Treg) cells that constitutively express LAG-3 (ref. 11).